>Европейский рынок препаратов для лечения аденомиоза по типу (диффузный, узловой, склеротический, кистозный у взрослых и другие), лечению (гормональные препараты, противовоспалительные препараты и другие), типу пациента (взрослые, гериатрические и подростковые), лекарственной форме (парентеральная, пероральная и другие), конечному пользователю (больницы, клиники, специализированные центры, домашняя медицинская помощь, амбулаторные центры и другие), каналу сбыта (больничная аптека , розничная аптека, интернет-аптека и другие) — тенденции отрасли и прогноз до 2029 года.
Анализ рынка и идеи
Аденомиоз — доброкачественное заболевание матки, при котором эндометриальные железы и строма патологически обнаруживаются в миометрии. Женщины, страдающие аденомиозом, могут иметь аномальные маточные кровотечения (АМК), дисменорею, диспареунию или бесплодие, но у трети из них симптомы отсутствуют. На протяжении многих лет аденомиоз оставался гистопатологическим диагнозом, который ставился после гистерэктомии у женщин в перименопаузе с обильными менструальными кровотечениями (ОМК) или тазовыми болями. Однако за последнее десятилетие аденомиоз также стал заболеванием, выявляемым у молодых женщин фертильного возраста из-за недавних достижений в методах визуализации, хотя единого определения и классификации все еще нет. Несмотря на улучшение диагностических инструментов, осведомленность об этом состоянии по-прежнему низкая.
Лекарственные средства, используемые для лечения аденомиоза, обычно включают противовоспалительные препараты и гормональные препараты, такие как аналоги гонадотропин-рилизинг-гормона (Gnrh Analogs), эстроген-прогестин, селективные модуляторы рецепторов прогестерона (SPRMs) или прогестин, ингибиторы ароматазы и антагонисты гонадотропин-рилизинг-гормона и т. д. Некоторые из этих препаратов используются для уменьшения размера аденомиотического поражения и улучшения дисменореи и качества жизни пациентки.
Спрос на препараты от аденомиоза увеличился больше в развитых странах. В этих странах была политика возмещения расходов на лечение наряду с высокой распространенностью заболевания и ростом расходов на здравоохранение. Рынок будет расти в прогнозируемый период за счет исследования развивающихся рынков и увеличения поддержки частных и государственных учреждений в лечении.
Отчет о рынке препаратов для лечения аденомиоза в Европе содержит подробную информацию о доле рынка, новых разработках, влиянии игроков на внутреннем и локальном рынке, анализирует возможности с точки зрения новых источников дохода, изменений в
Регламент рынка, одобрение продуктов, стратегические решения, запуски продуктов, географическое расширение и технологические инновации на рынке. Чтобы понять анализ и рыночный сценарий, свяжитесь с нами для получения аналитического брифинга. Наша команда поможет вам создать решение, влияющее на доход, для достижения желаемой цели. Стратегические инициативы, такие как сотрудничество, соглашение и подписание договоров купли-продажи для изобретения и внедрения инновационных фармакологических методов лечения, являются основными движущими силами, которые стимулировали спрос на рынке в прогнозируемый период.
Европейский рынок лекарств от аденомиоза является поддерживающим и направлен на замедление прогрессирования заболевания. Data Bridge Market Research анализирует, что рынок лекарств от аденомиоза в Европе будет расти со среднегодовым темпом роста 5,6% в течение прогнозируемого периода с 2022 по 2029 год.
|
Отчет Метрика |
Подробности |
|
Прогнозируемый период |
2022-2029 |
|
Базовый год |
2021 |
|
Исторические годы |
2020 (Можно настроить на 2019 - 2014) |
|
Количественные единицы |
Доход в тыс. долл. США, цены в долл. США |
|
Охваченные сегменты |
По типу (диффузный, узловой, склеротический, кистозный у взрослых и другие), лечению ( гормональные препараты, противовоспалительные препараты и другие), типу пациента (взрослые, гериатрические и подростковые), лекарственной форме (парентеральная, пероральная и другие), конечному пользователю (больницы, клиники, специализированные центры, домашняя медицинская помощь, амбулаторные центры и другие), каналу распространения (больничная аптека, розничная аптека, интернет-аптека и другие) |
|
Страны, охваченные |
Германия, Франция, Италия Великобритания, Испания, Россия, Австрия, Нидерланды, Венгрия, Польша, Швейцария, Турция, Норвегия, Литва, Ирландия, Остальная Европа |
|
Охваченные участники рынка |
Mayne Pharma Group Limited, Accord Healthcare, Boehringer Ingelheim International GmbH, Ferring BV, Par Pharmaceutical (дочерняя компания Endo International plc), Hikma Pharmaceuticals PLC, Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd. и другие. |
Определение рынка
Аденомиоз представляет собой уникальное патофизиологическое состояние, при котором нормально выглядящая слизистая оболочка эндометрия находится внутри миометрия и, таким образом, защищена от менструального отторжения. Предполагается, что возникающее эктопическое присутствие эндометриальной ткани, состоящей из желез и стромы, влияет на нормальную сократительную функцию и перистальтику гладких мышц матки, вызывая менометроррагию, бесплодие и неблагоприятные акушерские исходы. Аденомиоз налагает существенное социально-экономическое бремя из-за возросшей медицинской помощи и потери производительности труда, не говоря уже об ухудшении качества жизни.
Аденомиоз в большом проценте случаев негативно влияет на качество жизни женщин из-за аномальных маточных кровотечений и боли, требующих пожизненного плана лечения с помощью медикаментозного или хирургического лечения. Выбор зависит от возраста женщины, ее репродуктивного статуса и клинических симптомов. Однако заболевание все чаще диагностируется у молодых женщин с репродуктивным желанием, и предпочтение отдается консервативным методам лечения, таким как гормональные препараты.
Динамика рынка лекарств от аденомиоза в Европе
Драйверы
- Высокая распространенность заболеваний, связанных с аденомиозом
Гинекологические расстройства влияют на женскую репродуктивную систему. Наиболее распространенные симптомы гинекологических расстройств включают тазовую боль, эндометриоз , аденомиоз, аномальное вагинальное кровотечение, а также боль и уплотнения в груди и другие. Значимость и тяжесть этих симптомов часто зависят от возраста, так как эти симптомы могут быть связаны с гормональными изменениями, которые происходят со старением.
С ростом численности женщин во всем мире увеличилась и целевая группа для женского репродуктивного расстройства. Аденомиоз, гинекологическое заболевание, характеризующееся наличием эндометриальных желез и стромы в миометрии, может значительно ухудшить образ жизни человека. Аденомиоз встречается у 8,8–61,5% женщин, перенесших гистерэктомию, и показатели сильно различаются из-за различий в диагностических критериях и различий между патологами и внутри них. По оценкам, распространенность составляет от 20% до 34% на основе данных о пациентках, направленных на тазовую визуализацию, а не общей популяции женщин.
- Прогресс в диагностике аденомиоза
Развитие методов визуализации, таких как МРТ и трансвагинальное УЗИ (ТВУЗИ), позволило врачам проводить неинвазивную диагностику аденомиоза у женщин, также проходящих консервативное лечение, выявляя различные фенотипы заболевания. После нескольких попыток гистологической классификации аденомиоз подразделяют на четыре подтипа в зависимости от локализации очага МРТ во внутреннем или наружном миометрии: внутренний, внешний, интрамуральный и неопределенный.
Возможность
- Увеличение спроса на лекарственное лечение конкретных заболеваний
Согласно патогенным механизмам, несколько медицинских гормональных и негормональных методов лечения используются не по назначению для лечения боли и кровотечения и улучшения результатов фертильности. Использование GnRHa показано перед лечением фертильности для повышения шансов наступления беременности у бесплодных женщин с аденомиозом, и самая высокая частота наступления беременности зарегистрирована у тех, кто проходит перенос замороженных эмбрионов после предварительного лечения GnRHa. Напротив, использование GnRHa для лечения боли и кровотечения следует рассматривать только для краткосрочного лечения из-за менопаузальных эффектов. Внутриматочная система с высвобождением левоноргестрела (LNG-IUS) также является эффективным, обратимым и долгосрочным методом лечения, успешно применяемым для лечения аденомиоза. Результаты показывают, что она уменьшает менструальное кровотечение, боль и объем матки и имеет общую удовлетворенность 72%. Однако для лечения аденомиоза разрабатываются новые препараты, такие как селективные модуляторы рецепторов прогестерона, ингибиторы ароматазы, вальпроевая кислота и антиагрегантная терапия.
Ограничения/Проблемы
Диагностические тесты на аденомиоз включают в себя высокотехнологичные передовые продукты. Разработка этих продуктов включает в себя строгие исследования и разработки со стороны разработчика. Таким образом, стоимость продукта остается высокой, что пропорционально увеличивает стоимость тестирования. Диагностические инструменты и методы, используемые для диагностики аденомиоза, включают эндометриому яичников, спайки и глубокие узловые формы заболевания, для обнаружения которых часто требуется УЗИ или магнитно-резонансная томография (МРТ). Гистологическая проверка, обычно следующая за хирургической/лапароскопической визуализацией, может быть полезна для подтверждения диагноза, особенно для наиболее распространенных поверхностных поражений.
Терапия аденомиоза включает различные стадии и различные процедуры лечения. Аденомиоз можно лечить хирургическим путем, гормональными препаратами, противовоспалительными препаратами и т. д. Диагностика аденомиоза сложна, и это впоследствии приводит к трудностям в лечении этих пациенток, особенно тех, у кого нет симптомов, но есть сильное желание сохранить матку. В качестве альтернативных методов лечения аденомиоза используются растительные препараты и домашние средства.
Последние события
- В октябре 2021 года швейцарская биофармацевтическая компания Азиатско-Тихоокеанского региона Debiopharm и ведущая индонезийская фармацевтическая компания Dexa Medica объявили о запуске в Индонезии трипторелина для лечения женщин с гинекологическими заболеваниями, в частности аденомиозом и связанными с ним заболеваниями.
- В сентябре 2019 года профессору Кэролайн Гаргетт и ее коллегам из Университета Квинсленда и центра ЭКО Монаша был предоставлен трехлетний грант в размере 2,07 млн долларов США (3,05 млн австралийских долларов) для определения причины аденомиоза и физиологических процессов, связанных с этим заболеванием.
Европейский рынок лекарств от аденомиоза разделился
Европейский рынок лекарств от аденомиоза подразделяется на шесть основных сегментов, которые основаны на типе, лечении, типе пациента, лекарственной форме, канале сбыта и конечном пользователе. Рост среди сегментов помогает вам анализировать нишевые области роста и стратегии выхода на рынок, а также определять основные области применения и разницу в ваших целевых рынках.
Тип
- Диффузный
- Узелковый
- склеротический
- Кистозный взрослый
- Другие
По типу заболевания рынок препаратов для лечения аденомиоза в Европе сегментируется на диффузный, узловой, склеротический, кистозный аденомиоз у взрослых и другие.
Уход
- Гормональные препараты
- Противовоспалительные препараты
- Другие
По характеру лечения европейский рынок препаратов для лечения аденомиоза сегментирован на гормональные препараты, противовоспалительные препараты и другие.
Тип пациента
- Подростковый возраст
- Взрослый
- гериатрический
В зависимости от типа пациента европейский рынок препаратов для лечения аденомиоза сегментирован на подростковый, взрослый и гериатрический.
Лекарственная форма
- Парентеральный
- Оральный
- Другие
По форме выпуска европейский рынок препаратов для лечения аденомиоза сегментируется на парентеральные, пероральные и другие.
Конечный пользователь
- Больницы
- Клиники
- Специализированный центр
- Медицинская помощь на дому
- Амбулаторные центры
- Другие
По типу конечного потребителя европейский рынок препаратов для лечения аденомиоза сегментирован на больницы, клиники, специализированные центры, учреждения по оказанию медицинской помощи на дому, амбулаторные центры и другие.
Канал распространения
- Больничная аптека
- Розничная аптека
- Интернет-аптека
- Другие
По каналам сбыта рынок препаратов для лечения аденомиоза в Европе сегментируется на больничные аптеки, розничные аптеки, интернет-аптеки и другие.
Европейский рынок лекарств от аденомиоза. Региональный анализ/информация
Проведен анализ европейского рынка препаратов для лечения аденомиоза, а также предоставлены сведения о размерах рынка и тенденциях по типу, лечению, типу пациента, лекарственной форме, каналу сбыта и конечному пользователю, как указано выше.
В отчете о европейском рынке препаратов для лечения аденомиоза рассматриваются следующие страны: Германия, Франция, Италия, Великобритания, Испания, Россия, Австрия, Нидерланды, Венгрия, Польша, Швейцария, Турция, Норвегия, Литва, Ирландия и остальные страны Европы.
Ожидается, что Германия будет доминировать на рынке в течение прогнозируемого периода из-за роста расходов на здравоохранение в стране.
Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании рынка, которые влияют на текущие и будущие тенденции рынка. Такие данные, как анализ цепочки создания стоимости вверх и вниз по течению, технические тенденции, анализ пяти сил Портера и тематические исследования, являются некоторыми из указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по странам рассматриваются наличие и доступность европейских брендов и их проблемы, связанные с большой или малой конкуренцией со стороны местных и отечественных брендов, влияние внутренних тарифов и торговые пути.
Конкурентная среда и анализ доли рынка препаратов для лечения аденомиоза в Европе
Конкурентная среда европейского рынка лекарств от аденомиоза содержит сведения о конкурентах. Включены сведения о компании, финансы компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, присутствие в Европе, производственные площадки и объекты, производственные мощности, сильные и слабые стороны компании, запуск продукта, широта и широта продукта и доминирование в применении. Приведенные выше данные относятся только к фокусу компаний на европейском рынке лекарств от аденомиоза.
Некоторые из ключевых игроков на рынке: Mayne Pharma Group Limited, Accord Healthcare, Boehringer Ingelheim International GmbH, Ferring BV, Par Pharmaceutical (дочерняя компания Endo International plc), Hikma Pharmaceuticals PLC, Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd. и другие.
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Рыночные данные анализируются и оцениваются с использованием рыночных статистических и когерентных моделей. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в рыночном отчете. Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Помимо этого, модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, анализ доли компании на рынке, стандарты измерения, Европа против региона и анализ доли поставщика. Пожалуйста, запросите звонок аналитика в случае дальнейшего запроса.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE ADENOMYOSIS DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS FOR ADENOMYOSIS DRUGS MARKET
7 EUROPE ADENOMYOSIS DRUGS MARKET: REGULATORY SCENARIO
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 HIGH PREVALENCE OF ADENOMYOSIS DISORDERS
8.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF ADENOMYOSIS DRUG
8.1.3 ADVANCEMENT IN DIAGNOSIS OF ADENOMYOSIS
8.1.4 INCREASING AWARENESS OF ADENOMYOSIS
8.2 RESTRAINTS
8.2.1 HIGH COST OF TESTING AND MEDICATIONS
8.2.2 ADVERSE SIDE-EFFECTS OF ADENOMYOSIS DRUGS
8.3 OPPORTUNITIES
8.3.1 INCREASE DEMAND FOR DISEASE-SPECIFIC DRUG TREATMENT
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.3.3 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT
8.4 CHALLENGES
8.4.1 ALTERNATIVE ADENOMYOSIS THERAPIES
8.4.2 IMPROPER DIAGNOSIS OF ADENOMYOSIS
9 EUROPE ADENOMYOSIS DRUGS MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIFFUSE
9.2.1 BY SYMPTOMS
9.2.1.1 MENORRHAGIA
9.2.1.2 PELVIC PAIN
9.2.1.3 DYSMENORRHEA
9.2.1.4 METRORRHAGIA
9.2.1.5 OTHERS
9.2.2 BY AGE
9.2.2.1 BETWEEN 20 TO 45
9.2.2.2 ABOVE 45
9.2.2.3 BEFORE 20
9.3 NODULAR
9.3.1 BY SYMPTOMS
9.3.1.1 MENORRHAGIA
9.3.1.2 PELVIC PAIN
9.3.1.3 DYSMENORRHEA
9.3.1.4 METRORRHAGIA
9.3.1.5 OTHERS
9.3.2 BY AGE
9.3.2.1 BETWEEN 20 TO 45
9.3.2.2 ABOVE 45
9.3.2.3 BEFORE 20
9.4 SCLEROTIC
9.4.1 BY SYMPTOMS
9.4.1.1 MENORRHAGIA
9.4.1.2 PELVIC PAIN
9.4.1.3 DYSMENORRHEA
9.4.1.4 METRORRHAGIA
9.4.1.5 OTHERS
9.4.2 BY AGE
9.4.2.1 BETWEEN 20 TO 45
9.4.2.2 ABOVE 45
9.4.2.3 BEFORE 20
9.5 ADULT CYSTIC
9.5.1 BY SYMPTOMS
9.5.1.1 MENORRHAGIA
9.5.1.2 PELVIC PAIN
9.5.1.3 DYSMENORRHEA
9.5.1.4 METRORRHAGIA
9.5.1.5 OTHERS
9.5.2 BY AGE
9.5.2.1 BETWEEN 20 TO 45
9.5.2.2 ABOVE 45
9.5.2.3 BEFORE 20
9.6 OTHERS
9.6.1 ATYPICAL POLYPOID ADENOMYOMAS
9.6.1.1 BY SYMPTOMS
9.6.1.1.1 MENORRHAGIA
9.6.1.1.2 PELVIC PAIN
9.6.1.1.3 DYSMENORRHEA
9.6.1.1.4 METRORRHAGIA
9.6.1.1.5 OTHERS
9.6.1.2 BY AGE
9.6.1.2.1 BETWEEN 20 TO 45
9.6.1.2.2 ABOVE 45
9.6.1.2.3 BEFORE 20
9.6.2 JUVENILE CYSTIC ADENOMYOSIS
9.6.2.1 BY SYMPTOMS
9.6.2.1.1 MENORRHAGIA
9.6.2.1.2 PELVIC PAIN
9.6.2.1.3 DYSMENORRHEA
9.6.2.1.4 METRORRHAGIA
9.6.2.1.5 OTHERS
9.6.2.2 BY AGE
9.6.2.2.1 BETWEEN 20 TO 45
9.6.2.2.2 ABOVE 45
9.6.2.2.3 BEFORE 20
10 EUROPE ADENOMYOSIS DRUGS MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 HORMONE MEDICATIONS
10.2.1 GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS)
10.2.1.1 LEUPROLIDE ACETATE
10.2.1.2 NAFARELIN
10.2.1.3 GOSERELIN
10.2.1.4 OTHERS
10.2.2 ESTROGEN-PROGESTIN
10.2.2.1 ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P)
10.2.2.2 CONJUGATED ESTROGENS (E) + MEDROXYPROGESTERONE ACETATE (P)
10.2.2.3 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P)
10.2.2.4 OTHERS
10.2.3 SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN
10.2.3.1 LEVONORGESTREL
10.2.3.2 MIFEPRISTONE
10.2.3.3 ASOPRISNIL
10.2.3.4 LONAPRISAN
10.2.3.5 TELAPRISTONE ACETATE
10.2.3.6 ULIPRISTAL ACETATE
10.2.3.7 ONAPRISTONE
10.2.4 AROMATASE INHIBITORS
10.2.4.1 ARIMIDEX
10.2.4.2 FEMARA
10.2.4.3 OTHERS
10.2.5 GONADOTROPIN-RELEASING HORMONE ANTAGONIST
10.2.5.1 ELAGOLIX
10.2.5.2 FIRMAGON
10.2.5.3 OTHERS
10.2.6 SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)
10.2.6.1 TAMOXIFEN
10.2.6.2 RALOXIFENE
10.2.6.3 BAZEDOXIFENE
10.2.6.4 CLOMIPHENE
10.2.6.5 TOREMIFENE
10.2.6.6 OSPEMIFENE
10.2.6.7 LASOFOXIFENE
10.2.7 ANDROGEN DERIVATIVES
10.2.7.1 DANAZOL
10.2.7.2 GESTRINONE
10.3 ANTI-INFLAMMATORY DRUGS
10.3.1 NON-SELECTIVE NSAIDS
10.3.1.1 IBUPROFEN
10.3.1.2 NAPROXEN
10.3.1.3 DICLOFENAC
10.3.1.4 MEFENAMIC ACID
10.3.1.5 PIROXICAM
10.3.1.6 OTHERS
10.3.2 SELECTIVE COX-2 NSAIDS
10.3.2.1 CELECOXIB
10.3.2.2 VALDECOXIB
10.3.2.3 OTHERS
10.3.3 PREFERENTIAL COX-2 INHIBITORS
10.3.3.1 MELOXICAM
10.3.3.2 ETODOLAC
10.3.3.3 OTHERS
10.4 OTHERS
11 EUROPE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE
11.1 OVERVIEW
11.2 ADULT
11.3 GERIATRIC
11.4 ADOLESCENCE
12 EUROPE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLETS
12.2.2 CAPSULES
12.2.3 SOLUTION
12.2.4 SUSPENSION
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 INTRAMUSCULAR
12.4 OTHERS
13 EUROPE ADENOMYOSIS DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 SPECIALTY CENTER
13.5 HOME HEALTHCARE
13.6 AMBULATORY CENTERS
13.7 OTHERS
14 EUROPE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
14.5 OTHERS
15 EUROPE ADENOMYOSIS DRUGS MARKET, BY REGION
15.1 EUROPE
15.1.1 GERMANY
15.1.2 U.K.
15.1.3 FRANCE
15.1.4 ITALY
15.1.5 SPAIN
15.1.6 RUSSIA
15.1.7 NETHERLANDS
15.1.8 SWITZERLAND
15.1.9 POLAND
15.1.10 TURKEY
15.1.11 HUNGARY
15.1.12 AUSTRIA
15.1.13 NORWAY
15.1.14 IRELAND
15.1.15 LITHUANIA
15.1.16 REST OF EUROPE
16 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: EUROPE
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 ABBVIE INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.1.5.1 ACQUISITION
18.1.5.2 PARTNERSHIP
18.2 PFIZER INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.2.5.1 MERGER
18.3 SANOFI
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.3.5.1 MERGER
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.4.5.1 PARTNERSHIP
18.5 BAYER AG
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.5.5.1 ACQUISITION
18.6 ABBOTT
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.6.4.1 PRODUCT APPROVAL
18.7 ACCORD HEALTHCARE
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENT
18.8 AMNEAL PHARMACEUTICALS LLC
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.8.4.1 EVENT
18.9 ASTRAZENECA
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.9.4.1 EXPANSION
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENT
18.11 CONTEXT THERAPEUTICS INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.11.3.1 EVENT
18.12 DR. REDDY’S LABORATORIES LTD.
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENT
18.12.4.1 ACQUISITION
18.13 FERRING B.V.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENTS
18.13.3.1 COLLABORATION
18.14 GLAXOSMITHKLINE PLC
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.14.4.1 PARTNERSHIP
18.15 HIKMA PHARMACEUTICALS PLC
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 JOHNSON & JOHNSON SERVICES, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.16.4.1 EVENT
18.17 LANNETT
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENT
18.17.4.1 EVENT
18.18 MAYNE PHARMA GROUP LIMITED
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.18.4.1 PRODUCT LAUNCH
18.19 NOVARTIS AG
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENTS
18.19.4.1 PRODUCT DEVELOPMENT
18.19.4.2 ACQUISITION
18.2 PAR PHARMACEUTICAL ( A SUBSIDIARY OF ENDO INTERNATIONAL PLC)
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENTS
18.21 SUN PHARMACEUTICAL INDUSTRIES LTD
18.21.1 COMPANY SNAPSHOT
18.21.2 REVENUE ANALYSIS
18.21.3 PRODUCT PORTFOLIO
18.21.4 RECENT DEVELOPMENT
18.22 TERSERA THERAPEUTICS LLC
18.22.1 COMPANY SNAPSHOT
18.22.2 PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENT
18.22.3.1 AGREEMENT
18.23 TOLMAR PHARMACEUTICALS, INC.
18.23.1 COMPANY SNAPSHOT
18.23.2 PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENT
18.23.3.1 PRODUCT LAUNCH
18.23.3.2 EXPANSION
18.24 VIATRIS INC
18.24.1 COMPANY SNAPSHOT
18.24.2 REVENUE ANALYSIS
18.24.3 PRODUCT PORTFOLIO
18.24.4 RECENT DEVELOPMENT
18.24.4.1 AGREEMENT
18.25 ZYDUS PHARMACEUTICALS, INC.
18.25.1 COMPANY SNAPSHOT
18.25.2 PRODUCT PORTFOLIO
18.25.3 RECENT DEVELOPMENTS
18.25.3.1 ACQUISITION
19 QUESTIONNAIRE
20 RELATED REPORTS
Список таблиц
TABLE 1 EUROPE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 2 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 3 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 4 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 5 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 6 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 7 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 8 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 9 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 10 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 11 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 12 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 13 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 14 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 15 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 16 EUROPE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 17 EUROPE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 18 EUROPE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 19 EUROPE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 20 EUROPE ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 21 EUROPE HORMONE MEDICATION IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 22 EUROPE HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 23 EUROPE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 24 EUROPE ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 25 EUROPE SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 26 EUROPE AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 27 EUROPE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 28 EUROPE SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 29 EUROPE ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 30 EUROPE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 31 EUROPE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 32 EUROPE NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 33 EUROPE SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 34 EUROPE PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 35 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 36 EUROPE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 37 EUROPE ADULT IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 38 EUROPE GERIATRIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 39 EUROPE ADOLESCENCE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 EUROPE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 41 EUROPE ORAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 42 EUROPE ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 43 EUROPE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 44 EUROPE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 45 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 46 EUROPE ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 47 EUROPE HOSPITAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 48 EUROPE CLINICS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 49 EUROPE SPECIALTY CENTER IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 50 EUROPE HOME HEALTHCARE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 51 EUROPE AMBULATORY CENTERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 52 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 53 EUROPE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 54 EUROPE HOSPITAL PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 55 EUROPE RETAIL PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 56 EUROPE ONLINE PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 57 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 58 EUROPE ADENOMYOSIS DRUGS MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 59 EUROPE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 60 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 61 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 62 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 63 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 64 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 65 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 66 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 67 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 68 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 69 EUROPE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 70 EUROPE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 71 EUROPE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 72 EUROPE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 73 EUROPE ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 74 EUROPE HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 75 EUROPE GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 76 EUROPE ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 77 EUROPE SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 78 EUROPE AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 79 EUROPE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 80 EUROPE SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 81 EUROPE ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 82 EUROPE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 83 EUROPE NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 84 EUROPE SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 85 EUROPE PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 86 EUROPE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 87 EUROPE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 88 EUROPE ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 89 EUROPE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 90 EUROPE ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 91 EUROPE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 92 GERMANY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 93 GERMANY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 94 GERMANY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 95 GERMANY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 96 GERMANY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 97 GERMANY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 98 GERMANY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 99 GERMANY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 100 GERMANY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 101 GERMANY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 102 GERMANY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 103 GERMANY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 104 GERMANY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 105 GERMANY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 106 GERMANY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 107 GERMANY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 108 GERMANY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 109 GERMANY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 110 GERMANY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 111 GERMANY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 112 GERMANY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 113 GERMANY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 114 GERMANY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 115 GERMANY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 116 GERMANY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 117 GERMANY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 118 GERMANY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 119 GERMANY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 120 GERMANY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 121 GERMANY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 122 GERMANY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 123 GERMANY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 124 GERMANY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 125 U.K. ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 126 U.K. DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 127 U.K. DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 128 U.K. NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 129 U.K. NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 130 U.K. SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 131 U.K. SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 132 U.K. ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 133 U.K. ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 134 U.K. OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 135 U.K. ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 136 U.K. ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 137 U.K. JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 138 U.K. JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 139 U.K. ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 140 U.K. HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 141 U.K. GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 142 U.K. ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 143 U.K. SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 144 U.K. AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 145 U.K. GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 146 U.K. SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 147 U.K. ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 148 U.K. ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 149 U.K. NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 150 U.K. SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 151 U.K. PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 152 U.K. ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 153 U.K. ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 154 U.K. ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 155 U.K. PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 156 U.K. ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 157 U.K. ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 158 FRANCE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 159 FRANCE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 160 FRANCE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 161 FRANCE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 162 FRANCE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 163 FRANCE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 164 FRANCE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 165 FRANCE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 166 FRANCE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 167 FRANCE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 168 FRANCE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 169 FRANCE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 170 FRANCE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 171 FRANCE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 172 FRANCE ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 173 FRANCE HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 174 FRANCE GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 175 FRANCE ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 176 FRANCE SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 177 FRANCE AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 178 FRANCE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 179 FRANCE SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 180 FRANCE ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 181 FRANCE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 182 FRANCE NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 183 FRANCE SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 184 FRANCE PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 185 FRANCE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 186 FRANCE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 187 FRANCE ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 188 FRANCE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 189 FRANCE ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 190 FRANCE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 191 ITALY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 192 ITALY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 193 ITALY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 194 ITALY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 195 ITALY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 196 ITALY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 197 ITALY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 198 ITALY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 199 ITALY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 200 ITALY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 201 ITALY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 202 ITALY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 203 ITALY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 204 ITALY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 205 ITALY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 206 ITALY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 207 ITALY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 208 ITALY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 209 ITALY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 210 ITALY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 211 ITALY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 212 ITALY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 213 ITALY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 214 ITALY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 215 ITALY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 216 ITALY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 217 ITALY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 218 ITALY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 219 ITALY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 220 ITALY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 221 ITALY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 222 ITALY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 223 ITALY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 224 SPAIN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 225 SPAIN DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 226 SPAIN DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 227 SPAIN NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 228 SPAIN NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 229 SPAIN SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 230 SPAIN SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 231 SPAIN ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 232 SPAIN ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 233 SPAIN OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 234 SPAIN ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 235 SPAIN ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 236 SPAIN JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 237 SPAIN JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 238 SPAIN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 239 SPAIN HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 240 SPAIN GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 241 SPAIN ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 242 SPAIN SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 243 SPAIN AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 244 SPAIN GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 245 SPAIN SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 246 SPAIN ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 247 SPAIN ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 248 SPAIN NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 249 SPAIN SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 250 SPAIN PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 251 SPAIN ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 252 SPAIN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 253 SPAIN ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 254 SPAIN PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 255 SPAIN ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 256 SPAIN ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 257 RUSSIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 258 RUSSIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 259 RUSSIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 260 RUSSIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 261 RUSSIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 262 RUSSIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 263 RUSSIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 264 RUSSIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 265 RUSSIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 266 RUSSIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 267 RUSSIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 268 RUSSIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 269 RUSSIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 270 RUSSIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 271 RUSSIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 272 RUSSIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 273 RUSSIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 274 RUSSIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 275 RUSSIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 276 RUSSIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 277 RUSSIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 278 RUSSIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 279 RUSSIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 280 RUSSIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 281 RUSSIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 282 RUSSIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 283 RUSSIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 284 RUSSIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 285 RUSSIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 286 RUSSIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 287 RUSSIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 288 RUSSIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 289 RUSSIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 290 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 291 NETHERLANDS DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 292 NETHERLANDS DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 293 NETHERLANDS NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 294 NETHERLANDS NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 295 NETHERLANDS SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 296 NETHERLANDS SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 297 NETHERLANDS ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 298 NETHERLANDS ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 299 NETHERLANDS OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 300 NETHERLANDS ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 301 NETHERLANDS ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 302 NETHERLANDS JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 303 NETHERLANDS JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 304 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 305 NETHERLANDS HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 306 NETHERLANDS GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 307 NETHERLANDS ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 308 NETHERLANDS SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 309 NETHERLANDS AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 310 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 311 NETHERLANDS SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 312 NETHERLANDS ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 313 NETHERLANDS ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 314 NETHERLANDS NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 315 NETHERLANDS SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 316 NETHERLANDS PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 317 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 318 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 319 NETHERLANDS ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 320 NETHERLANDS PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 321 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 322 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 323 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 324 SWITZERLAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 325 SWITZERLAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 326 SWITZERLAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 327 SWITZERLAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 328 SWITZERLAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 329 SWITZERLAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 330 SWITZERLAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 331 SWITZERLAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 332 SWITZERLAND OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 333 SWITZERLAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 334 SWITZERLAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 335 SWITZERLAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 336 SWITZERLAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 337 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 338 SWITZERLAND HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 339 SWITZERLAND GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 340 SWITZERLAND ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 341 SWITZERLAND SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 342 SWITZERLAND AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 343 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 344 SWITZERLAND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 345 SWITZERLAND ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 346 SWITZERLAND ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 347 SWITZERLAND NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 348 SWITZERLAND SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 349 SWITZERLAND PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 350 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 351 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 352 SWITZERLAND ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 353 SWITZERLAND PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 354 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 355 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 356 POLAND ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 357 POLAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 358 POLAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 359 POLAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 360 POLAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 361 POLAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 362 POLAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 363 POLAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 364 POLAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 365 POLAND OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 366 POLAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 367 POLAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 368 POLAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 369 POLAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 370 POLAND ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 371 POLAND HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 372 POLAND GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 373 POLAND ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 374 POLAND SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 375 POLAND AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 376 POLAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 377 POLAND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 378 POLAND ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 379 POLAND ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 380 POLAND NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 381 POLAND SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 382 POLAND PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 383 POLAND ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 384 POLAND ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 385 POLAND ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 386 POLAND PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 387 POLAND ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 388 POLAND ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 389 TURKEY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 390 TURKEY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 391 TURKEY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 392 TURKEY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 393 TURKEY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 394 TURKEY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 395 TURKEY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 396 TURKEY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 397 TURKEY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 398 TURKEY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 399 TURKEY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 400 TURKEY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 401 TURKEY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 402 TURKEY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 403 TURKEY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 404 TURKEY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 405 TURKEY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 406 TURKEY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 407 TURKEY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 408 TURKEY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 409 TURKEY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 410 TURKEY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 411 TURKEY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 412 TURKEY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 413 TURKEY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 414 TURKEY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 415 TURKEY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 416 TURKEY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 417 TURKEY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 418 TURKEY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 419 TURKEY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 420 TURKEY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 421 TURKEY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 422 HUNGARY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 423 HUNGARY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 424 HUNGARY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 425 HUNGARY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 426 HUNGARY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 427 HUNGARY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 428 HUNGARY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 429 HUNGARY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 430 HUNGARY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 431 HUNGARY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 432 HUNGARY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 433 HUNGARY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 434 HUNGARY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 435 HUNGARY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 436 HUNGARY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 437 HUNGARY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 438 HUNGARY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 439 HUNGARY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 440 HUNGARY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 441 HUNGARY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 442 UNGARY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 443 HUNGARY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 444 HUNGARY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 445 HUNGARY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 446 HUNGARY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 447 HUNGARY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 448 HUNGARY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 449 HUNGARY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 450 HUNGARY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 451 HUNGARY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 452 HUNGARY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 453 HUNGARY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 454 HUNGARY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 455 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 456 AUSTRIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 457 AUSTRIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 458 AUSTRIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 459 AUSTRIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 460 AUSTRIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 461 AUSTRIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 462 AUSTRIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 463 AUSTRIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 464 AUSTRIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 465 AUSTRIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 466 AUSTRIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 467 AUSTRIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 468 AUSTRIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 469 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 470 AUSTRIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 471 AUSTRIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 472 AUSTRIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 473 AUSTRIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 474 AUSTRIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 475 AUSTRIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 476 AUSTRIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 477 AUSTRIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 478 AUSTRIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 479 AUSTRIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 480 AUSTRIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 481 AUSTRIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 482 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 483 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 484 AUSTRIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 485 AUSTRIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 486 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 487 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 488 NORWAY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 489 NORWAY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 490 NORWAY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 491 NORWAY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 492 NORWAY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 493 NORWAY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 494 NORWAY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 495 NORWAY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 496 NORWAY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 497 NORWAY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 498 NORWAY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 499 NORWAY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 500 NORWAY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 501 NORWAY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 502 NORWAY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 503 NORWAY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 504 NORWAY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 505 NORWAY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 506 NORWAY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 507 NORWAY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 508 NORWAY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 509 NORWAY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 510 NORWAY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 511 NORWAY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 512 NORWAY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 513 NORWAY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 514 NORWAY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 515 NORWAY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 516 NORWAY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 517 NORWAY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 518 NORWAY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 519 NORWAY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 520 NORWAY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 521 IRELAND ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 522 IRELAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 523 IRELAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 524 IRELAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 525 IRELAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 526 IRELAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 527 IRELAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 528 IRELAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 529 IRELAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 530 IRELAND OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 531 IRELAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 532 IRELAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 533 IRELAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 534 IRELAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 535 IRELAND ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 536 IRELAND HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 537 IRELAND GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 538 IRELAND ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 539 IRELAND SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 540 IRELAND AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 541 IRELAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 542 IRELAND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 543 IRELAND ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 544 IRELAND ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 545 IRELAND NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 546 IRELAND SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 547 IRELAND PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 548 IRELAND ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 549 IRELAND ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 550 IRELAND ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 551 IRELAND PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 552 IRELAND ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 553 IRELAND ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 554 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 555 LITHUANIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 556 LITHUANIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 557 LITHUANIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 558 LITHUANIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 559 LITHUANIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 560 LITHUANIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 561 LITHUANIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 562 LITHUANIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 563 LITHUANIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 564 LITHUANIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 565 LITHUANIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 566 LITHUANIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 567 LITHUANIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 568 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 569 LITHUANIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 570 LITHUANIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 571 LITHUANIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 572 LITHUANIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 573 LITHUANIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 574 LITHUANIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 575 LITHUANIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 576 LITHUANIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 577 LITHUANIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 578 LITHUANIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 579 LITHUANIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 580 LITHUANIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 581 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 582 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 583 LITHUANIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 584 LITHUANIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 585 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 586 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 587 REST OF EUROPE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
Список рисунков
FIGURE 1 EUROPE ADENOMYOSIS DRUGS MARKET: SEGMENTATION
FIGURE 2 EUROPE ADENOMYOSIS DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE ADENOMYOSIS DRUGS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE ADENOMYOSIS DRUGS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE ADENOMYOSIS DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE ADENOMYOSIS DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE ADENOMYOSIS DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE ADENOMYOSIS DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE ADENOMYOSIS DRUGS MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE ADENOMYOSIS DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE ADENOMYOSIS DRUGS MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN EUROPE ADENOMYOSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 HIGH PREVALENCE OF ADENOMYOSIS DISORDER AND INCREASE THE RESEARCH AND DEVELOPMENT OF ADENOMYOSIS DRUG ARE DRIVING THE EUROPE ADENOMYOSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DIFFUSE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ADENOMYOSIS DRUGS MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ADENOMYOSIS DRUGS MARKET
FIGURE 16 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE, 2021
FIGURE 17 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE, 2022-2029 (USD THOUSAND)
FIGURE 18 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 EUROPE ADENOMYOSIS DRUGS MARKET: BY TREATMENT, 2021
FIGURE 21 EUROPE ADENOMYOSIS DRUGS MARKET: BY TREATMENT, 2022-2029 (USD THOUSAND)
FIGURE 22 EUROPE ADENOMYOSIS DRUGS: BY TREATMENT, CAGR (2022-2029)
FIGURE 23 EUROPE ADENOMYOSIS DRUGS: BY TREATMENT, LIFELINE CURVE
FIGURE 24 EUROPE ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, 2021
FIGURE 25 EUROPE ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)
FIGURE 26 EUROPE ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 27 EUROPE ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 28 EUROPE ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, 2021
FIGURE 29 EUROPE ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)
FIGURE 30 EUROPE ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 31 EUROPE ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 32 EUROPE ADENOMYOSIS DRUGS MARKET: BY END USER, 2021
FIGURE 33 EUROPE ADENOMYOSIS DRUGS MARKET: BY END USER, 2022-2029 (USD THOUSAND)
FIGURE 34 EUROPE ADENOMYOSIS DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 35 EUROPE ADENOMYOSIS DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 36 EUROPE ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 37 EUROPE ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)
FIGURE 38 EUROPE ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 39 EUROPE ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 EUROPE ADENOMYOSIS DRUGS MARKET : SNAPSHOT (2021)
FIGURE 41 EUROPE ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2021)
FIGURE 42 EUROPE ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 43 EUROPE ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 44 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE (2022-2029)
FIGURE 45 EUROPE ADENOMYOSIS DRUGS MARKET: COMPANY SHARE 2021 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.
